ID   XCT_HUMAN               Reviewed;         501 AA.
AC   Q9UPY5; A8K2U4;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   18-JUN-2025, entry version 196.
DE   RecName: Full=Cystine/glutamate transporter {ECO:0000305};
DE   AltName: Full=Amino acid transport system xc-;
DE   AltName: Full=Calcium channel blocker resistance protein CCBR1;
DE   AltName: Full=Solute carrier family 7 member 11;
DE   AltName: Full=xCT {ECO:0000303|PubMed:11213471};
GN   Name=SLC7A11 {ECO:0000312|HGNC:HGNC:11059};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.
RX   PubMed=11213471; DOI=10.1089/ars.2000.2.4-665;
RA   Sato H., Tamba M., Kuriyama-Matsumura K., Okuno S., Bannai S.;
RT   "Molecular cloning and expression of human xCT, the light chain of amino
RT   acid transport system xc-.";
RL   Antioxid. Redox Signal. 2:665-671(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Conklin D.S., Beach D.H.;
RT   "CCBR1, novel CD98 light chain implicated in redox control and calcium
RT   signaling.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11417227; DOI=10.1007/s004240100537;
RA   Bassi M.T., Gasol E., Manzoni M., Pineda M., Riboni M., Martin R.,
RA   Zorzano A., Borsani G., Palacin M.;
RT   "Identification and characterisation of human xCT that co-expresses, with
RT   4F2 heavy chain, the amino acid transport activity system xc-.";
RL   Pflugers Arch. 442:286-296(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.
RC   TISSUE=Placenta;
RX   PubMed=11133847;
RA   Bridges C.C., Kekuda R., Wang H., Prasad P.D., Mehta P., Huang W.,
RA   Smith S.B., Ganapathy V.;
RT   "Structure, function, and regulation of human cystine/glutamate transporter
RT   in retinal pigment epithelial cells.";
RL   Invest. Ophthalmol. Vis. Sci. 42:47-54(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF CYS-86; CYS-158; CYS-271; CYS-327; CYS-414
RP   AND CYS-435.
RX   PubMed=14722095; DOI=10.1074/jbc.m309866200;
RA   Jimenez-Vidal M., Gasol E., Zorzano A., Nunes V., Palacin M., Chillaron J.;
RT   "Thiol modification of cysteine 327 in the eighth transmembrane domain of
RT   the light subunit xCT of the heteromeric cystine/glutamate antiporter
RT   suggests close proximity to the substrate binding site/permeation
RT   pathway.";
RL   J. Biol. Chem. 279:11214-11221(2004).
RN   [9]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MEMBRANE
RP   TOPOLOGY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-86; CYS-158;
RP   CYS-197; CYS-271; CYS-327; CYS-414 AND CYS-435.
RX   PubMed=15151999; DOI=10.1074/jbc.m402428200;
RA   Gasol E., Jimenez-Vidal M., Chillaron J., Zorzano A., Palacin M.;
RT   "Membrane topology of system xc- light subunit reveals a re-entrant loop
RT   with substrate-restricted accessibility.";
RL   J. Biol. Chem. 279:31228-31236(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=34120018; DOI=10.1016/j.placenta.2021.05.009;
RA   Lofthouse E.M., Manousopoulou A., Cleal J.K., O'Kelly I.M., Poore K.R.,
RA   Garbis S.D., Lewis R.M.;
RT   "N-acetylcysteine, xCT and suppression of Maxi-chloride channel activity in
RT   human placenta.";
RL   Placenta 110:46-55(2021).
RN   [14]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=35245456; DOI=10.1016/j.molcel.2022.02.007;
RA   Fiore A., Zeitler L., Russier M., Gross A., Hiller M.K., Parker J.L.,
RA   Stier L., Koecher T., Newstead S., Murray P.J.;
RT   "Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling.";
RL   Mol. Cell 82:920-932(2022).
RN   [15] {ECO:0007744|PDB:7P9U, ECO:0007744|PDB:7P9V}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 2-501 IN COMPLEX WITH
RP   L-GLUTAMATE AND SLC3A2, FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF
RP   ARG-135; LYS-198; PHE-336 AND ARG-396.
RX   PubMed=34880232; DOI=10.1038/s41467-021-27414-1;
RA   Parker J.L., Deme J.C., Kolokouris D., Kuteyi G., Biggin P.C., Lea S.M.,
RA   Newstead S.;
RT   "Molecular basis for redox control by the human cystine/glutamate
RT   antiporter system xc.";
RL   Nat. Commun. 12:7147-7147(2021).
RN   [16] {ECO:0007744|PDB:7EPZ}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 2-501 IN COMPLEX WITH
RP   SLC3A2 AND ERASTIN INHIBITOR, FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, DISULFIDE BOND, AND MUTAGENESIS OF GLN-191; PHE-254 AND
RP   PHE-336.
RX   PubMed=35352032; DOI=10.1038/s41422-022-00642-w;
RA   Yan R., Xie E., Li Y., Li J., Zhang Y., Chi X., Hu X., Xu L., Hou T.,
RA   Stockwell B.R., Min J., Zhou Q., Wang F.;
RT   "The structure of erastin-bound xCT-4F2hc complexreveals molecular
RT   mechanisms underlying erastin-induced ferroptosis.";
RL   Cell Res. 32:687-690(2022).
CC   -!- FUNCTION: Heterodimer with SLC3A2, that functions as an antiporter by
CC       mediating the exchange of extracellular anionic L-cystine and
CC       intracellular L-glutamate across the cellular plasma membrane
CC       (PubMed:11133847, PubMed:11417227, PubMed:14722095, PubMed:15151999,
CC       PubMed:34880232, PubMed:35245456, PubMed:35352032). Provides L-cystine
CC       for the maintenance of the redox balance between extracellular L-
CC       cystine and L-cysteine and for the maintenance of the intracellular
CC       levels of glutathione that is essential for cells protection from
CC       oxidative stress (By similarity). The transport is sodium-independent,
CC       electroneutral with a stoichiometry of 1:1, and is drove by the high
CC       intracellular concentration of L-glutamate and the intracellular
CC       reduction of L-cystine (PubMed:11133847, PubMed:11417227). In addition,
CC       mediates the import of L-kynurenine leading to anti-ferroptotic
CC       signaling propagation required to maintain L-cystine and glutathione
CC       homeostasis (PubMed:35245456). Moreover, mediates N-acetyl-L-cysteine
CC       uptake into the placenta leading to subsequently down-regulation of
CC       pathways associated with oxidative stress, inflammation and apoptosis
CC       (PubMed:34120018). In vitro can also transport L-aspartate
CC       (PubMed:11417227). May participate in astrocyte and meningeal cell
CC       proliferation during development and can provide neuroprotection by
CC       promoting glutathione synthesis and delivery from non-neuronal cells
CC       such as astrocytes and meningeal cells to immature neurons (By
CC       similarity). Controls the production of pheomelanin pigment directly
CC       (By similarity). {ECO:0000250|UniProtKB:Q9WTR6,
CC       ECO:0000269|PubMed:11133847, ECO:0000269|PubMed:11417227,
CC       ECO:0000269|PubMed:14722095, ECO:0000269|PubMed:15151999,
CC       ECO:0000269|PubMed:34120018, ECO:0000269|PubMed:34880232,
CC       ECO:0000269|PubMed:35245456, ECO:0000269|PubMed:35352032}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-cystine(out) + L-glutamate(in) = L-cystine(in) + L-
CC         glutamate(out); Xref=Rhea:RHEA:70995, ChEBI:CHEBI:29985,
CC         ChEBI:CHEBI:35491; Evidence={ECO:0000269|PubMed:11133847,
CC         ECO:0000269|PubMed:11417227, ECO:0000269|PubMed:14722095,
CC         ECO:0000269|PubMed:15151999, ECO:0000269|PubMed:34880232,
CC         ECO:0000269|PubMed:35245456, ECO:0000269|PubMed:35352032};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an L-alpha-amino acid(in) + L-kynurenine(out) = an L-alpha-
CC         amino acid(out) + L-kynurenine(in); Xref=Rhea:RHEA:71191,
CC         ChEBI:CHEBI:57959, ChEBI:CHEBI:59869;
CC         Evidence={ECO:0000269|PubMed:35245456};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-acetyl-L-cysteine(out) + L-glutamate(in) = N-acetyl-L-
CC         cysteine(in) + L-glutamate(out); Xref=Rhea:RHEA:74567,
CC         ChEBI:CHEBI:29985, ChEBI:CHEBI:78236;
CC         Evidence={ECO:0000269|PubMed:34120018};
CC   -!- ACTIVITY REGULATION: Inhibited by erastin and sulfasalazine
CC       (PubMed:35352032). Inhibited by (S)-lactate (PubMed:11417227).
CC       Inactivated by p-chloromercuribenzoic acid and p-
CC       chloromercuribenzenesulfonic acid (PubMed:14722095).
CC       {ECO:0000269|PubMed:11417227, ECO:0000269|PubMed:14722095,
CC       ECO:0000269|PubMed:35352032}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=48 uM for L-glutamate {ECO:0000269|PubMed:11133847};
CC         KM=224 uM for L-glutamate {ECO:0000269|PubMed:15151999};
CC         KM=110 uM for L-cystine {ECO:0000269|PubMed:15151999};
CC         KM=92 uM for L-glutamate {ECO:0000269|PubMed:11417227};
CC         KM=43 uM for L-cystine {ECO:0000269|PubMed:11417227};
CC         KM=173 uM for L-glutamate {ECO:0000269|PubMed:14722095};
CC         Vmax=6087 pmol/min/mg enzyme toward L-glutamate
CC         {ECO:0000269|PubMed:15151999};
CC         Vmax=9597 pmol/min/mg enzyme toward L-cystine
CC         {ECO:0000269|PubMed:15151999};
CC   -!- SUBUNIT: Disulfide-linked heterodimer with the amino acid transport
CC       protein SLC3A2/4F2hc; this interaction mediates cell membrane
CC       localization. {ECO:0000269|PubMed:11417227,
CC       ECO:0000269|PubMed:34880232}.
CC   -!- INTERACTION:
CC       Q9UPY5; P16070: CD44; NbExp=4; IntAct=EBI-3843348, EBI-490245;
CC       Q9UPY5; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-3843348, EBI-11959885;
CC       Q9UPY5; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-3843348, EBI-11749135;
CC       Q9UPY5; P08195: SLC3A2; NbExp=2; IntAct=EBI-3843348, EBI-702356;
CC       Q9UPY5; P08195-4: SLC3A2; NbExp=3; IntAct=EBI-3843348, EBI-12832276;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11417227,
CC       ECO:0000269|PubMed:15151999, ECO:0000269|PubMed:34880232}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:15151999}. Cell projection,
CC       microvillus membrane {ECO:0000269|PubMed:34120018}; Multi-pass membrane
CC       protein {ECO:0000255}. Note=Localized to the microvillous membrane of
CC       the placental syncytiotrophoblast. {ECO:0000269|PubMed:34120018}.
CC   -!- TISSUE SPECIFICITY: Expressed in term placenta and primary term
CC       cytotrophoblast (PubMed:34120018). Expressed mainly in the brain, but
CC       also in pancreas (PubMed:11417227). {ECO:0000269|PubMed:11417227,
CC       ECO:0000269|PubMed:34120018}.
CC   -!- INDUCTION: By oxygen in a concentration-dependent manner
CC       (PubMed:11213471). Up-regulated by S-nitroso-N-acetyl-D-penicillamine
CC       (PubMed:11133847). {ECO:0000269|PubMed:11133847,
CC       ECO:0000269|PubMed:11213471}.
CC   -!- PTM: Ubiquitinated by TRIM26; leading to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:Q9WTR6}.
CC   -!- SIMILARITY: Belongs to the amino acid-polyamine-organocation (APC)
CC       superfamily. L-type amino acid transporter (LAT) (TC 2.A.3.8) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: In the PMID:15151999, a typographical error has been
CC       introduced leading to L-cysteine spelling instead of L-cystine.
CC       {ECO:0000305|PubMed:15151999}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB026891; BAA82628.1; -; mRNA.
DR   EMBL; AF200708; AAG35592.1; -; mRNA.
DR   EMBL; AJ277882; CAC81905.1; -; mRNA.
DR   EMBL; AF252872; AAK49111.1; -; mRNA.
DR   EMBL; AK290359; BAF83048.1; -; mRNA.
DR   EMBL; AK314855; BAG37372.1; -; mRNA.
DR   EMBL; CH471056; EAX05135.1; -; Genomic_DNA.
DR   EMBL; BC012087; AAH12087.1; -; mRNA.
DR   CCDS; CCDS3742.1; -.
DR   RefSeq; NP_055146.1; NM_014331.4.
DR   PDB; 7CCS; EM; 6.20 A; B=1-501.
DR   PDB; 7EPZ; EM; 3.40 A; B=2-501.
DR   PDB; 7P9U; EM; 3.70 A; B=2-501.
DR   PDB; 7P9V; EM; 3.40 A; B=2-501.
DR   PDBsum; 7CCS; -.
DR   PDBsum; 7EPZ; -.
DR   PDBsum; 7P9U; -.
DR   PDBsum; 7P9V; -.
DR   AlphaFoldDB; Q9UPY5; -.
DR   EMDB; EMD-13266; -.
DR   EMDB; EMD-13267; -.
DR   EMDB; EMD-31251; -.
DR   SMR; Q9UPY5; -.
DR   BioGRID; 117179; 144.
DR   ComplexPortal; CPX-8190; XCT-4F2 heteromeric amino acid transporter complex.
DR   FunCoup; Q9UPY5; 230.
DR   IntAct; Q9UPY5; 39.
DR   MINT; Q9UPY5; -.
DR   STRING; 9606.ENSP00000280612; -.
DR   BindingDB; Q9UPY5; -.
DR   ChEMBL; CHEMBL1075149; -.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB05540; Alanosine.
DR   DrugBank; DB00138; Cystine.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugBank; DB00740; Riluzole.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB00795; Sulfasalazine.
DR   DrugBank; DB08833; Taurochenodeoxycholic acid.
DR   DrugBank; DB04348; Taurocholic acid.
DR   DrugBank; DB08834; Tauroursodeoxycholic acid.
DR   DrugBank; DB11590; Thimerosal.
DR   DrugCentral; Q9UPY5; -.
DR   GuidetoPHARMACOLOGY; 902; -.
DR   TCDB; 2.A.3.8.18; the amino acid-polyamine-organocation (apc) family.
DR   GlyCosmos; Q9UPY5; 1 site, No reported glycans.
DR   GlyGen; Q9UPY5; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UPY5; -.
DR   PhosphoSitePlus; Q9UPY5; -.
DR   SwissPalm; Q9UPY5; -.
DR   BioMuta; SLC7A11; -.
DR   DMDM; 12585385; -.
DR   jPOST; Q9UPY5; -.
DR   MassIVE; Q9UPY5; -.
DR   PaxDb; 9606-ENSP00000280612; -.
DR   PeptideAtlas; Q9UPY5; -.
DR   ProteomicsDB; 85473; -.
DR   Pumba; Q9UPY5; -.
DR   Antibodypedia; 16136; 338 antibodies from 35 providers.
DR   DNASU; 23657; -.
DR   Ensembl; ENST00000280612.9; ENSP00000280612.5; ENSG00000151012.13.
DR   GeneID; 23657; -.
DR   KEGG; hsa:23657; -.
DR   MANE-Select; ENST00000280612.9; ENSP00000280612.5; NM_014331.4; NP_055146.1.
DR   UCSC; uc062zqn.1; human.
DR   AGR; HGNC:11059; -.
DR   CTD; 23657; -.
DR   DisGeNET; 23657; -.
DR   GeneCards; SLC7A11; -.
DR   HGNC; HGNC:11059; SLC7A11.
DR   HPA; ENSG00000151012; Tissue enhanced (brain).
DR   MIM; 607933; gene.
DR   OpenTargets; ENSG00000151012; -.
DR   VEuPathDB; HostDB:ENSG00000151012; -.
DR   eggNOG; KOG1287; Eukaryota.
DR   GeneTree; ENSGT00940000160324; -.
DR   HOGENOM; CLU_007946_3_0_1; -.
DR   InParanoid; Q9UPY5; -.
DR   OMA; PHWVWVL; -.
DR   OrthoDB; 10062876at2759; -.
DR   PAN-GO; Q9UPY5; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9UPY5; -.
DR   BioCyc; MetaCyc:ENSG00000151012-MONOMER; -.
DR   PathwayCommons; Q9UPY5; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-HSA-9818027; NFE2L2 regulating anti-oxidant/detoxification enzymes.
DR   SignaLink; Q9UPY5; -.
DR   SIGNOR; Q9UPY5; -.
DR   BioGRID-ORCS; 23657; 24 hits in 1186 CRISPR screens.
DR   ChiTaRS; SLC7A11; human.
DR   GeneWiki; SLC7A11; -.
DR   GenomeRNAi; 23657; -.
DR   Pharos; Q9UPY5; Tchem.
DR   PRO; PR:Q9UPY5; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9UPY5; protein.
DR   Bgee; ENSG00000151012; Expressed in cranial nerve II and 178 other cell types or tissues.
DR   ExpressionAtlas; Q9UPY5; baseline and differential.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0097449; C:astrocyte projection; IEA:Ensembl.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0031528; C:microvillus membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0015327; F:cystine:glutamate antiporter activity; IDA:UniProtKB.
DR   GO; GO:0015179; F:L-amino acid transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0140926; F:L-kynurenine transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0003333; P:amino acid transmembrane transport; IBA:GO_Central.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0140206; P:dipeptide import across plasma membrane; IEA:Ensembl.
DR   GO; GO:0006749; P:glutathione metabolic process; IEA:Ensembl.
DR   GO; GO:0034775; P:glutathione transmembrane transport; IEA:Ensembl.
DR   GO; GO:0090461; P:intracellular glutamate homeostasis; IEA:Ensembl.
DR   GO; GO:0015811; P:L-cystine transport; IDA:UniProtKB.
DR   GO; GO:0098712; P:L-glutamate import across plasma membrane; IEA:Ensembl.
DR   GO; GO:0015813; P:L-glutamate transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0140924; P:L-kynurenine transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0060173; P:limb development; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0110076; P:negative regulation of ferroptosis; IDA:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IEA:Ensembl.
DR   GO; GO:1904717; P:regulation of AMPA glutamate receptor clustering; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:1901494; P:regulation of cysteine metabolic process; IEA:Ensembl.
DR   GO; GO:2000211; P:regulation of glutamate metabolic process; IEA:Ensembl.
DR   GO; GO:1903786; P:regulation of glutathione biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048021; P:regulation of melanin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033029; P:regulation of neutrophil apoptotic process; IEA:Ensembl.
DR   GO; GO:0051223; P:regulation of protein transport; IEA:Ensembl.
DR   GO; GO:0050807; P:regulation of synapse organization; IEA:Ensembl.
DR   GO; GO:0051775; P:response to redox state; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   GO; GO:0021756; P:striatum development; IEA:Ensembl.
DR   GO; GO:0021591; P:ventricular system development; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   FunFam; 1.20.1740.10:FF:000027; cystine/glutamate transporter isoform X1; 1.
DR   Gene3D; 1.20.1740.10; Amino acid/polyamine transporter I; 1.
DR   InterPro; IPR002293; AA/rel_permease1.
DR   InterPro; IPR050598; AminoAcid_Transporter.
DR   InterPro; IPR004760; L_AA_transporter.
DR   NCBIfam; TIGR00911; 2A0308; 1.
DR   PANTHER; PTHR11785; AMINO ACID TRANSPORTER; 1.
DR   PANTHER; PTHR11785:SF323; CYSTINE_GLUTAMATE TRANSPORTER; 1.
DR   Pfam; PF13520; AA_permease_2; 1.
DR   PIRSF; PIRSF006060; AA_transporter; 1.
DR   neXtProt; NX_Q9UPY5; -.
DR   PharmGKB; PA35919; -.
DR   TreeFam; TF313355; -.
PE   1: Evidence at protein level;
KW   3D-structure; Amino-acid transport; Cell membrane; Cell projection;
KW   Disulfide bond; Glycoprotein; Membrane; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN           1..501
FT                   /note="Cystine/glutamate transporter"
FT                   /id="PRO_0000054279"
FT   TOPO_DOM        1..43
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        44..64
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        65..74
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        75..95
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        96..101
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   INTRAMEM        102..116
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        117..130
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        131..150
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        151..163
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        164..179
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        180..193
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        194..210
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        211..234
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        235..255
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        256..265
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        266..286
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        287..317
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        318..338
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        339..364
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        365..385
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        386..387
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        388..408
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        409..422
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        423..443
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        444..449
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TRANSMEM        450..470
FT                   /note="Helical"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   TOPO_DOM        471..501
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15151999"
FT   BINDING         135
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:34880232,
FT                   ECO:0007744|PDB:7P9U"
FT   BINDING         244
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:34880232,
FT                   ECO:0007744|PDB:7P9U"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   CARBOHYD        314
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        158
FT                   /note="Interchain (with C-210 in SLC3A2)"
FT                   /evidence="ECO:0000269|PubMed:35352032"
FT   MUTAGEN         86
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-158; S-197; S-271; S-327; S-414 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-158; S-197; S-271; S-327; S-414 and
FT                   S-435. Significantly increases L-glutamate affinity; when
FT                   associated with S-158; S-197; S-271; S-327; S-414 and
FT                   S-435. Does not affect inhibition of L-glutamate transport
FT                   activity by p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   MUTAGEN         135
FT                   /note="R->A: Loss of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         135
FT                   /note="R->K: Loss of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         158
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-197; S-271; S-327; S-414 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-197; S-271; S-327; S-414 and S-435.
FT                   Does not affect affinity for L-cystine; when associated
FT                   with S-86; S-197; S-271; S-327; S-414 and S-435.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-197; S-271; S-327; S-414 and S-435.
FT                   Does not affect inhibition of L-glutamate transport
FT                   activity by p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   MUTAGEN         191
FT                   /note="Q->A: Increases sensitivity to erastin-induced
FT                   ferroptosis."
FT                   /evidence="ECO:0000269|PubMed:35352032"
FT   MUTAGEN         197
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-158; S-271; S-327; S-414 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-158; S-271; S-327; S-414 and S-435.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-158; S-271; S-327; S-414 and
FT                   S-435."
FT                   /evidence="ECO:0000269|PubMed:15151999"
FT   MUTAGEN         198
FT                   /note="K->A: Loss of L-cystine transport activity. Does not
FT                   affect location at the celle membrane. Does not affect
FT                   expression level."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         254
FT                   /note="F->A: Increases resistance to erastin-induced
FT                   ferroptosis. Decreases sensitivity to erastin-induced
FT                   inhibition of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:35352032"
FT   MUTAGEN         271
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-158; S-197; S-327; S-414 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-158; S-197; S-327; S-414 and S-435.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-158; S-197; S-327; S-414 and S-435.
FT                   Does not affect inhibition of L-glutamate transport
FT                   activity by p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   MUTAGEN         327
FT                   /note="C->A: Does not affect L-glutamate transport
FT                   activity. Does not affect location at cell membrane Does
FT                   not affect expression level."
FT                   /evidence="ECO:0000269|PubMed:14722095"
FT   MUTAGEN         327
FT                   /note="C->L: Loss of L-glutamate transport activity. Does
FT                   not affect location at cell membrane. Does not affect
FT                   expression level."
FT                   /evidence="ECO:0000269|PubMed:14722095"
FT   MUTAGEN         327
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-158; S-197; S-271; S-414 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-158; S-197; S-271; S-414 and S-435.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-158; S-197; S-271; S-414 and S-435.
FT                   Loss of inhibitio nof L-glutamate transport activity by
FT                   p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid. Decrease L-glutamate
FT                   transport activity. Does not affect location at cell
FT                   membrane. Does not affect expression level."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   MUTAGEN         327
FT                   /note="C->T: Does not affect L-glutamate transport
FT                   activity. Does not affect location at cell membrane. Does
FT                   not affect expression level."
FT                   /evidence="ECO:0000269|PubMed:14722095"
FT   MUTAGEN         336
FT                   /note="F->A: Decreases L-cystine transport activity about
FT                   50%. Increases sensitivity to erastin-induced ferroptosis.
FT                   Significantly decreases the L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232,
FT                   ECO:0000269|PubMed:35352032"
FT   MUTAGEN         336
FT                   /note="F->Y: Does not affect L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         396
FT                   /note="R->A: Loss of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         396
FT                   /note="R->K: Loss of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         396
FT                   /note="R->N: Loss of L-cystine transport activity."
FT                   /evidence="ECO:0000269|PubMed:34880232"
FT   MUTAGEN         414
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-158; S-197; S-271; S-327 and
FT                   S-435. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-158; S-197; S-271; S-327 and S-435.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-158; S-197; S-271; S-327 and S-435.
FT                   Does not affect inhibition of L-glutamate transport
FT                   activity by p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   MUTAGEN         435
FT                   /note="C->S: Does not affect L-cystine transport activity;
FT                   when associated with S-86; S-158; S-197; S-271; S-327 and
FT                   S-414. Does not affect affinity for L-cystine; when
FT                   associated with S-86; S-158; S-197; S-271; S-327 and S-414.
FT                   Significantly increases L-glutamate affinity; when
FT                   associated with S-86; S-158; S-197; S-271; S-327 and S-414.
FT                   Does not affect inhibition of L-glutamate transport
FT                   activity by p-chloromercuribenzoic acid and
FT                   p-chloromercuribenzenesulfonic acid."
FT                   /evidence="ECO:0000269|PubMed:14722095,
FT                   ECO:0000269|PubMed:15151999"
FT   HELIX           46..57
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           61..71
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           76..104
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   STRAND          106..109
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           111..114
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            115..117
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           122..132
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           134..148
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           152..154
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:7P9V"
FT   HELIX           162..181
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           184..206
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            208..217
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            222..225
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           232..234
FT                   /evidence="ECO:0007829|PDB:7P9V"
FT   HELIX           235..243
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           244..246
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           249..251
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            256..258
FT                   /evidence="ECO:0007829|PDB:7P9V"
FT   STRAND          259..261
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            262..264
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           265..289
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            294..298
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           303..308
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           319..332
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            336..338
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           339..346
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            347..349
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            353..356
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   STRAND          358..362
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           366..381
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           385..412
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           426..441
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            442..444
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           447..458
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   HELIX           461..463
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            464..468
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   TURN            474..477
FT                   /evidence="ECO:0007829|PDB:7P9V"
FT   HELIX           478..492
FT                   /evidence="ECO:0007829|PDB:7EPZ"
FT   STRAND          494..497
FT                   /evidence="ECO:0007829|PDB:7P9V"
SQ   SEQUENCE   501 AA;  55423 MW;  3EF2648B94A9F59E CRC64;
     MVRKPVVSTI SKGGYLQGNV NGRLPSLGNK EPPGQEKVQL KRKVTLLRGV SIIIGTIIGA
     GIFISPKGVL QNTGSVGMSL TIWTVCGVLS LFGALSYAEL GTTIKKSGGH YTYILEVFGP
     LPAFVRVWVE LLIIRPAATA VISLAFGRYI LEPFFIQCEI PELAIKLITA VGITVVMVLN
     SMSVSWSARI QIFLTFCKLT AILIIIVPGV MQLIKGQTQN FKDAFSGRDS SITRLPLAFY
     YGMYAYAGWF YLNFVTEEVE NPEKTIPLAI CISMAIVTIG YVLTNVAYFT TINAEELLLS
     NAVAVTFSER LLGNFSLAVP IFVALSCFGS MNGGVFAVSR LFYVASREGH LPEILSMIHV
     RKHTPLPAVI VLHPLTMIML FSGDLDSLLN FLSFARWLFI GLAVAGLIYL RYKCPDMHRP
     FKVPLFIPAL FSFTCLFMVA LSLYSDPFST GIGFVITLTG VPAYYLFIIW DKKPRWFRIM
     SEKITRTLQI ILEVVPEEDK L
//
